VEGF-D Antibody [Biotin]

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Biotin
• Concentration: LYOPH

VEGF-D Antibody [Biotin] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human VEGF-D
  Phe93-Ser201
  Accession # O43915
• Specificity: Detects human VEGF-D in Western blots. In Western blots, approximately 20% cross‑reactivity with recombinant mouse VEGF-D (under non‑reducing conditions) is observed and less than 1% cross-reactivity with recombinant human (rh) VEGF and rhVEGF-B is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: FIGF
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.1 ug/mL
• Readout System:
  • Streptavidin Native Protein NBP2-29367
  • Streptavidin Native Protein NBP2-29370
  • Streptavidin Native Protein NBP2-29371

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VEGF-D Antibody [Biotin]

• c-fos induced growth factor (vascular endothelial growth factor D)
• FIGF
• vascular endothelial growth factor D
• VEGFD
• VEGF-D
• VEGF-DVEGFDc-Fos-induced growth factor

Background

Vascular endothelial growth factor D (VEGF-D), also known as c-fos-induced growth factor (FIGF), is a secreted glycoprotein of the VEGF/PDGF family. VEGFs regulate angiogenesis and lymphangiogenesis during development and tumor growth, and are characterized by eight conserved cysteine residues that form a cystine knot structure (1‑3). VEGF-C and VEGF-D, which share 23% amino acid (aa) sequence identity, are uniquely expressed as preproproteins that contain long N- and C‑terminal propeptide extensions around the VEGF homology domain (VHD) (1, 2). Proteolytic processing of the 354 aa VEGF-D preproprotein creates a secreted proprotein. Further processing by extracellular serine proteases, such as plasmin or furin-like proprotein convertases, forms mature VEGF-D consisting of non‑covalently linked 42 kDa homodimers of the 117 aa VHD (4‑6). Mature human VEGF-D shares 94%, 95%, 99%, 97%, and 93% aa identity with mouse, rat, equine, canine and bovine VEGF-D, respectively (4, 5). It is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin (1-4). Mouse and human VEGF-D are ligands for VEGF Receptor 3 (VEGF R3; also called Flt-4) that are active across species and show enhanced affinity when processed (7). Processed human VEGF-D is also a ligand for VEGF R2, also called Flk-1 or KDR (7). VEGF R3 is strongly expressed in lymphatic endothelial cells and is essential for regulation of the growth and differentiation of lymphatic endothelium (1, 2). While VEGF-C is the critical ligand for VEGF R3 during embryonic lymphatic development, VEGF-D is most active in neonatal lymphatic maturation and bone growth (8‑10). Both promote tumor lymphangiogenesis (11). Consonant with their activity on VEGF receptors, binding of VEGF-C and VEGF-D to neuropilins contributes to VEGF R3 signaling in lymphangiogenesis, while binding to integrin alpha 9 beta 1 mediates endothelial cell adhesion and migration (12, 13).

 

1. Roy, H. et al. (2006) FEBS Lett. 580:2879.
2. Otrock, Z.H. et al. (2007) Blood Cells Mol. Dis. 38:258.
3. Yamada, Y. et al. (1997) Genomics 42:483.
4. Stacker, S.A. et al. (1999) J. Biol. Chem. 274:32127.
5. McColl, B.K. et al. (2003) J. Exp. Med. 198:863.
6. McColl, B.K. et al. (2007) FASEB J. 21:1088.
7. Baldwin, M.E. et al. (2001) J. Biol. Chem. 276:19166.
8. Baldwin, M.E. et al. (2005) Mol. Cell. Biol. 25:2441.
9. Karpanen, T. et al. (2006) Am. J. Pathol. 169:708.
10. Orlandini, M. et al. (2006) J. Biol. Chem. 281:17961.
11. Stacker, S.A. et al. (2001) Nature Med. 7:186.
12. Karpanen, T. et al. (2006) FASEB J. 20:1462.
13. Vlahakis, N.E. et al. (2005) J. Biol. Chem. 280:4544.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VEGF-D Antibody (BAF286)(1)

Publication using BAF286

• Cassuto, J;Folestad, A;Göthlin, J;Malchau, H;Kärrholm, J; VEGF-A, -C, -D, VEGFR1, -2, -3, PDGF-BB and FGF-2 join forces to induce vascular and lymphatic angiogenesis during bone healing of hip implants Bone reports 2025-09-01 [PMID: 40688801] (ELISA Detection, Human)

Bioinformatics

• Gene Symbol: FIGF
• Uniprot:
  • O43915()